HBV RNA病毒样颗粒的潜在临床意义

肝脏 ›› 2016, Vol. 21 ›› Issue (9): 717-718.

• 社评与争鸣 • 下一篇

HBV RNA病毒样颗粒的潜在临床意义

中华肝脏病杂志临床肝胆病杂志《肝脏》杂志联合社评

100191 北京大学医学部基础医学院病原生物学系

收稿日期:2016-08-08 出版日期:2016-09-30 发布日期:2020-06-19
通讯作者: 鲁凤民,Email:lu.fengmin@bjmu.edu.cn

Potential clinical significance of HBV RNA virus-like particle

LU Feng-min, WANG Jie, ZHUANG Hui

Department of Microbiology & Infectious Disease Center, School of Basic Medicine, Peking UniversityHealth Science Center, Beijing 100191, China

Received:2016-08-08 Online:2016-09-30 Published:2020-06-19
Contact: LU Feng-min, Email: lu.fengmin@bjmu.edu.cn

摘要/Abstract

摘要： 最近的研究结果证实慢性乙型肝炎患者血清中存在的HBV RNA为3.5 kb的前基因组RNA(pgRNA),这些pgRNA 存在于形态结构类似于丹颗粒的病毒样颗粒中。由于pgRNA 只能由位于感染的肝细胞核内的病毒共价闭合环状DNA(cccDNA),且其产生过程不受核苷(酸)类抗病毒药物的影响,因此血清病毒RNA 应能够反映接受治疗的患者肝细胞内cccDNA的存在及转录活性。据此推测,血清病毒RNA 可作为一个潜在的指导核苷(酸)类似物安全停药的指标。基于小样本停药队列研究的结果显示停药点血清中HBV RNA的确与慢性乙型肝炎停药后的病毒学反弹相关。

关键词: 肝炎,乙型,慢性, 肝炎病毒,乙型, 治疗, 核苷(酸)类似物

Abstract: Our recent studies confirmed that the HBV RNAs present in the serum of chronic hepatitisB (CHB) patients are pregenomic RNAs (pgRNAs) with a size of 3.5 kb. These pgRNAs are located in viruslikeparticles whose morphological structure is similar to that of Dan particles. Since pgRNAs can only betranscribed from the covalently closed circular DNA (cccDNA) located in the nuclear of infected hepatocytes,and the production of pgRNAs is not affected by nucleos(t)ide analogues (NUCs), the presence of viral RNAin serum can reflect the presence of cccDNA in hepatocytes and its transcriptional activity in patients treatedwith medication. It can be inferred that serum viral RNA can be used as a potential index for safe withdrawal ofNUCs. Our results based on a small-sample cohort show that the presence of HBV RNA in serum at the time ofdrugs withdrawal is indeed associated with virological rebound after drug withdrawal.

Key words: Hepatitis B, chronic, Hepatitis B virus, Therapy, Nucleot(s)ide analogues

中华肝脏病杂志临床肝胆病杂志《肝脏》杂志联合社评. HBV RNA病毒样颗粒的潜在临床意义[J]. 肝脏, 2016, 21(9): 717-718.

LU Feng-min, WANG Jie, ZHUANG Hui. Potential clinical significance of HBV RNA virus-like particle[J]. Chinese Hepatolgy, 2016, 21(9): 717-718.

参考文献

[1] Kock J, Theilmann L, Galle P, et al. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology, 1996, 23: 405-413.
[2] JansenL, Kootstra NA, van Dort KA, et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues. J Infect Dis, 2016, 213: 224-232.
[3] Tsuge M, Murakami E, Imamura M, et al. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol, 2013, 48: 1188-1204.
[4] van Bommel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology, 2015, 61: 66-76.
[5] Wang J, Shen T, Huang X B, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol, 2016[Epub ahead of print].
[6] Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet, 2012, 44: 765-769.
[7] Jiang S, Yang Z, Li W, et al. Re-evaluation of the carcinogenic significance of hepatitis B virus integration in hepatocarcinogenesis. PLoS One, 2012, 7: e40363.
[8] Li X, Zhang J, Yang Z, et al. The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma. J Hepatol, 2014, 60: 975-984.
[9] Shouval D, Rager-Zisman B, Quan P, et al. Role in nude mice of interferon and natural killer cells in inhibiting the tumorigenicity of human hepatocellular carcinoma cells infected with hepatitis B virus. J Clin Invest, 1983, 72: 707-717.
[10] Shouval D, Reid LM, Chakraborty PR, et al. Tumorigenicity in nude mice of a human hepatoma cell line containing hepatitis B virus DNA. Cancer Res, 1981, 41: 1342-1350.

[1]	俞海英, 郭银燕, 丁巧云, 钟艳丹, 曹兴国, 杨永峰. 不同核苷(酸)类似物停药后病情变化的临床观察[J]. 肝脏, 2020, 25(4): 390-393.
[2]	高晓红, 郝晓芳, 景鹏. 不同核苷(酸)类药物长期治疗对乙型肝炎肝硬化的影响[J]. 肝脏, 2020, 25(4): 396-400.
[3]	李永涛, 卜贤玉, 李滨. 替诺福韦酯补救治疗对HBV感染肝硬化患者的疗效分析[J]. 肝脏, 2020, 25(4): 400-402.
[4]	孔媛媛, 魏巍, 单姗, 马红, 欧晓娟, 徐小元, 段钟平, 侯金林, 魏来, 尤红, 贾继东, 中国消除乙肝临床科研平台(CR-HepB)研究组. 乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化[J]. 肝脏, 2020, 25(2): 123-127.
[5]	马春明, 张锁才, 史罗明, 吴剑明, 周根法, 郑剑. 慢性乙型肝炎外周血浆样树突状细胞与免疫应答的关系及干预分析[J]. 肝脏, 2020, 25(1): 34-35.
[6]	张郴华, 钟备, 邓英, 李敏. 慢性乙型肝炎患者HBV核苷(酸)类似物预存耐药基因突变的研究[J]. 肝脏, 2020, 25(1): 39-41.
[7]	陆伟, 刘丹萍, 张占卿, 王雁冰, 丁荣蓉, 周新兰, 黄丹, 李秀芬, 杨可芷. APRI、GPR和FIB-4预测抗病毒诱导的乙型肝炎肝硬化肝脏病理学回归的性能评价[J]. 肝脏, 2019, 24(8): 875-882.
[8]	王艳, 姚甜甜, 钱建丹, 程浩, 王贵强. 慢性乙型肝炎患者核苷(酸)类似物停药后复发预测因素meta分析[J]. 肝脏, 2019, 24(7): 744-751.
[9]	谭文敏, 赖庭文, 韩锋. IL-28B基因多态性对直接抗病毒药物治疗慢性丙型肝炎患者疗效的预测价值[J]. 肝脏, 2019, 24(7): 776-779.
[10]	武丽萍, 李鸿彬, 许晓东. 合并脂肪肝对慢性乙型肝炎患者抗病毒治疗后病毒学应答的影响[J]. 肝脏, 2019, 24(6): 655-658.
[11]	张炎, 陶苗苗, 侯庆兵. 膈顶部肝癌超声引导的射频消融治疗效果在不同腹水量患者中的差异对比[J]. 肝脏, 2019, 24(6): 664-666.
[12]	梁栋, 张燕, 董晓锋, 朱晓红, 王建斌, 刘妲妲, 王全楚. 以不明原因发热首诊的细菌性肝脓肿89例临床分析[J]. 肝脏, 2019, 24(6): 704-706.
[13]	李晓涛, 李涛. 转移性肝脏肿瘤患者行介入治疗后肝脓肿发病状况研究[J]. 肝脏, 2019, 24(5): 544-546.
[14]	刘伟, 李海涛. 肝动脉介入栓塞术和微波消融治疗对B、C期肝癌患者术后远期疗效比较[J]. 肝脏, 2019, 24(5): 561-563.
[15]	金宏慧, 胡晨波, 陈晓蓉, 陆云飞, 冯艳玲. 核苷(酸)类似物抗HBV获得病毒学应答后生化学持续不应答临床分析[J]. 肝脏, 2019, 24(4): 365-367.

HBV RNA病毒样颗粒的潜在临床意义

Potential clinical significance of HBV RNA virus-like particle

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价